Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs by KATIE THOMAS


By KATIE THOMAS

The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.

Published: July 24, 2017 at 08:00PM

from NYT Health http://ift.tt/2uvw3P1
via IFTTT

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s